Experts Tell Congressional Briefing FDA Lets Bad Generics On Market
This article was originally published in PharmAsia News
A group of physician experts and others told a U.S. Congressional briefing that many unqualified generic drugs are reaching the market despite FDA, many of them ineffective or harmful to patients.
You may also be interested in...
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway